MSAM
DNA icon

Moloney Securities Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Moloney Securities Asset Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-500
Closed -$6.69K – 496
2024
Q2 		$6.69K Hold
500
– – ﹤0.01% 459
2024
Q1 		$23.2K Sell
500
-1,500
-75% -$77.6K ﹤0.01% 442
2023
Q4 		$135K Hold
2,000
– – 0.02% 418
2023
Q3 		$145K Hold
2,000
– – 0.03% 392
2023
Q2 		$149K Sell
2,000
-38
-2% -$2.25K 0.03% 388
2023
Q1 		$108K Sell
2,038
-428
-17% -$27.1K 0.02% 393
2022
Q4 		$167K Buy
2,466
+803
+48% +$73.9K 0.04% 365
2022
Q3 		$207K Buy
+1,663
New +$198K 0.05% 332

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Moloney Securities Asset Management's DNA Position: Q3 2024 in Review

Moloney Securities Asset Management sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 500 shares — an estimated $6.69K sold.

Moloney Securities Asset Management first reported a position in DNA in Q3 2022 and held it in 8 quarters. The position peaked at $207K in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Moloney Securities Asset Management reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Moloney Securities Asset Management sold 500 Ginkgo Bioworks shares in Q3 2024, an estimated $6.69K.
  • Moloney Securities Asset Management first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 8 quarters.
  • Moloney Securities Asset Management's Ginkgo Bioworks position peaked at $207K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Moloney Securities Asset Management's 13F filing for Q3 2024, filed 30 Oct 2024.